옥스카르바제핀 복용 후 발생한 양안의 백내장
Bilateral Cataract after Taking Oxcarbazepine
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
목적: 젊은 환자에서 항경련제인 옥스카르바제핀(Oxcarbazepine, Trileptal®, Novartis, Basel, Swiss) 복용 후 발생한 수정체 피막하 백내장 증례를 경험하였기에 이를 보고하고자 한다. 증례요약: 19세 여자 환자가 1년 전부터 발생한 양안 시력저하를 주소로 내원하였다. 교정시력은 우안 0.3, 좌안 0.5였고, 세극등검사상 양안 수정체 피질 백내장 및 피막하 백내장 소견이 발견되었으며 이외에 특이 소견은 관찰되지 않았다. 백내장 위험인자에 대해 환자의 과거력, 약물력, 가족력 등에 대해 문진하였고, 과거력상 뇌전증 진단하에 10년간 옥스카르바제핀을 복용하였고 3년 전부터 중단한 상태였으며, 어머니가 46세경 백내장수술을 받은 가족력이 있었다. 그 외 백내장을 유발할만한 위험인자는 발견되지 않았다. 결론: 옥스카르바제핀이 백내장을 유발하였을 가능성이 있으므로 백내장 발생 시 옥스카르바제핀 복용도 가능한 원인 중 하나로 고려되어야 하며, 옥스카르바제핀을 복용하고 있는 환자의 경우 정기적인 안과 검진이 필요할 것으로 생각된다.
Abstract
Purpose: To report a case of bilateral posterior subcapsular cataract after taking oxcarbazepine (Trileptal®, Novartis, Basel, Swiss). Case summary: A 19-year-old female visited our clinic with decreased vision in both eyes. Her best-corrected visual acuity was 0.3 in the right eye and 0.5 in the left eye, and slit-lamp examination revealed a bilateral cortical opacity and subcapsular cataract. She had been taking oxcarbazepine for epilepsy for 10 years, which was discontinued 3 years ago. Her mother had undergone cataract surgeries when she was approximately 46 years of age. No other risk factors for cataract were present. Conclusions: In the present case, bilateral cortical opacity and subcapsular cataract were assumed to be associated with the use of oxcarbazepine. We suggest that oxcarbazepine could induce a cataract and recommend a regular follow-up by a qualified ophthalmologist.
참고문헌 (15)
- Stables JP, "Progress report on new antiepileptic drugs. A summary of the Second Eilat Conference", Epilepsy Res, 22, pp.235~246 (1995)
- Tecoma ES, "Oxcarbazepine", Epilepsia, 40(Suppl 5), pp.S37~46 (1999)
- Bill PA, "A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in adults with previously untreated epilepsy", Epilepsy Res, 27, pp.195~204 (1997)
- Guerreiro MM, "A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in children and adolescents with epilepsy", Epilepsy Res, 27, pp.205~213 (1997)
- Christe W, "A double-blind controlled clinical trial : oxcarbazepine versus sodium valproate in adults with newly diagnosed epilepsy", Epilepsy Res, 26, pp.451~460 (1997)
- Friis ML, "Therapeutic experiences with 947 epileptic out-patients in oxcarbazepine treatment", Acta Neurol Scand, 87, pp.224~227 (1993)
- McLean MJ, "Oxcarbazepine: mechanisms of action", Epilepsia, 35(Suppl 3), pp.S5~9 (1994)
- May TW, "Clinical pharmacokinetics of oxcarbazepine", Clin Pharmacokinet, 42, pp.1023~1042 (2003)
- van den Brûle J, "Drug-induced cataracts", Rev Med Liege, 53, pp.766~769 (1998)
- Berman ER, "Biochemistry of the Eye" (1991), Springer Science & Business Media
- Nita M, "The role of the reactive oxygen species and oxidative stress in the pathomechanism of the age-related ocular diseases and other pathologies of the anterior and posterior eye segments in adults", Oxid Med Cell Longev, 2016, pp.3164734~ (2016)
- Brown M, "Clinical pharmacology", pp.349~370 (2008), Churchill Livingstone Elsevier
- Flesch G, "Overview of the clinical pharmacokinetics of oxcarbazepine", Clin Drug Investig, 24, pp.185~203 (2004)
- Banergee S, "Drug metabolism and oxidative stress : cellular mechanism and new therapeutic insights", Biochem Anal Biochem, 5, pp.255~ (2016)
- Pham-Huy LA, "Free radicals, antioxidants in disease and health", Int J Biomed Sci, 4, pp.89~96 (2008)